Exchange of Letters on Blood Plasma Products

The Honourable Robert B. Zoellick
United States Trade Representative
600 17th Street, NW
Washington, DC  20508

Dear Ambassador Zoellick:

In connection with the signing on this date of the Australia-United States Free Trade Agreement (the “Agreement”), I have the honour to confirm the following understanding reached by the Governments of Australia and the United States regarding treatment to be accorded products derived from blood plasma (“blood plasma products”) and blood fractionation services for the production of such products:

1. Any contract with a central government entity of Australia for blood fractionation services in effect on the date of entry into force of this Agreement shall conclude no later than 31 December 2009 or earlier if Australia deems it appropriate;

2. Australia shall undertake a review of its arrangements for the supply of blood fractionation services that will be concluded by no later than 1 January 2007. The Commonwealth Government will recommend to Australia’s States and Territories that future arrangements for the supply of such services be done through tender processes consistent with Chapter 15 (Government Procurement).

3. Should the Commonwealth and State and Territory governments reach agreement to move to tender processes consistent with Chapter 15 (Government Procurement), Australia shall withdraw its Annex 15-E reservation to that chapter;

4. A Party may require that any producer of blood plasma products or supplier of blood fractionation services fulfil requirements necessary for ensuring the safety, quality and efficacy of such products. Such requirements shall not be prepared, adopted, or applied with a view to or with the effect of creating unnecessary obstacles to trade;

5. A Party may require that blood plasma products for use in its territory be derived from blood plasma collected in the territory of that Party; and
6. Australia confirms that it will not apply any requirement for an applicant for approval of the marketing and distribution of a U.S. blood plasma product to demonstrate significant clinical advantage over Australian-produced products.

I have the honour to propose that this letter constitute an integral part of the Agreement and that Article 21.2(c) (Scope of Application) of the Agreement applies.

Sincerely

MARK VAILE
The Honourable Mark Vaile  
Minister for Trade  
Parliament House  
Canberra ACT 2600

Dear Minister Vaile:

I have the honour to confirm receipt of your letter of this date regarding the treatment to be accorded to blood plasma products and blood fractionation services, which reads as follows:

“Dear Ambassador Zoellick:

In connection with the signing on this date of the Australia-United States Free Trade Agreement (the “Agreement”), I have the honour to confirm the following understanding reached by the Governments of Australia and the United States regarding treatment to be accorded products derived from blood plasma ("blood plasma products") and blood fractionation services for the production of such products:

1. Any contract with a central government entity of Australia for blood fractionation services in effect on the date of entry into force of this Agreement shall conclude no later than 31 December 2009 or earlier if Australia deems it appropriate;

2. Australia shall undertake a review of its arrangements for the supply of blood fractionation services that will be concluded by no later than 1 January 2007. The Commonwealth Government will recommend to Australia’s States and Territories that future arrangements for the supply of such services are done through tender processes consistent with Chapter 15 (Government Procurement);

3. Should the Commonwealth and State and Territory governments reach agreement to move to tender processes consistent with Chapter 15 (Government Procurement), Australia shall withdraw its Annex 15-E reservation to that chapter;

4. A Party may require that any producer of blood plasma products or supplier of blood fractionation services fulfil requirements necessary for ensuring the safety, quality and efficacy of such products. Such requirements
shall not be prepared, adopted, or applied with a view to or with the effect of creating unnecessary obstacles to trade;

5. A Party may require that blood plasma products for use in its territory be derived from blood plasma collected in the territory of that Party; and

6. Australia confirms that it will not apply any requirement for an applicant for approval of the marketing and distribution of a U.S. blood plasma product to demonstrate significant clinical advantage over Australian produced products.

I have the honour to propose that this letter and your letter in reply constitute an integral part of the Agreement and that Article 21.2(c) (Scope of Application) of the Agreement applies.

Sincerely

MARK VAILE”

I have the further honour to confirm that your letter and this reply constitute an integral part of the Agreement and that Article 21.2(c) (Scope of Application) of the Agreement applies. The United States expects that Australia will undertake any future arrangements for blood fractionation services through tender processes consistent with Chapter 15 (Government Procurement) of the Agreement.

Sincerely,

Robert B. Zoellick